



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


# PRODUCT INFORMATION



## Cilazaprilat

Item No. 38118

**CAS Registry No.:** 90139-06-3  
**Formal Name:** (1S,9S)-9-[[[(1S)-1-carboxy-3-phenylpropyl] amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid  
**Synonym:** Ro 31-3113  
**MF:** C<sub>20</sub>H<sub>27</sub>N<sub>3</sub>O<sub>5</sub>  
**FW:** 389.5  
**Purity:** ≥98%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Cilazaprilat is supplied as a solid. A stock solution may be made by dissolving the cilazaprilat in the solvent of choice, which should be purged with an inert gas. Cilazaprilat is slightly soluble in DMSO.

### Description

Cilazaprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC<sub>50</sub> = 0.7 nM for the rat enzyme) and an active metabolite of cilazapril (Item No. 29777).<sup>1,2</sup> It decreases creatine kinase release in primary neonatal rat cardiac myocytes in an *in vitro* model of ischemia-reperfusion injury induced by hypoxia and reoxygenation when used at a concentration of 10 μM.<sup>3</sup> Intra-arterial administration of cilazaprilat (3 μg/kg per minute) increases coronary blood flow and fractional shortening in a dog model of coronary hypoperfusion-induced myocardial ischemia.<sup>4</sup>

### References

1. Perich, R.B., Jackson, B., and Johnston, C.I. Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme. *Eur. J. Pharmacol.* **266(3)**, 201-211 (1994).
2. Takai, S., Matsuda, A., Usami, Y., *et al.* Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver. *Bio. Pharm. Bull.* **20(8)**, 869-873 (1997).
3. Matoba, S., Tatsumi, T., Keira, N., *et al.* Cardioprotective effect of angiotensin-converting enzyme inhibition against hypoxia/reoxygenation injury in cultured rat cardiac myocytes. *Circulation* **99(6)**, 817-822 (1999).
4. Kitakaze, M., Minamino, T., Node, K., *et al.* Beneficial effects of inhibition of angiotensin-converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. *Circulation* **92(4)**, 950-961 (1995).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/28/2023

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM